Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3910
Name lung adenocarcinoma
Definition A lung non-small cell carcinoma that derives_from epithelial cells of glandular origin.
Source DiseaseOntology.org
Alt Ids DOID:4826 DOID:3909
Path disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma lung adenocarcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MAP2K1 K57N Selumetinib lung adenocarcinoma sensitive detail...
PIK3CA H1047R Dactolisib lung adenocarcinoma sensitive detail...
PIK3CA H1047R Sirolimus lung adenocarcinoma no benefit detail...
FBXW7 R465H Temsirolimus lung adenocarcinoma sensitive detail...
ROS1 rearrange Crizotinib lung adenocarcinoma sensitive detail...
ALK rearrange ALK I1171T Alectinib lung adenocarcinoma resistant detail...
ALK rearrange ALK I1171T Crizotinib lung adenocarcinoma resistant detail...
MAP2K1 Q56P Trametinib lung adenocarcinoma sensitive detail...
MAP2K1 Q56P Selumetinib lung adenocarcinoma sensitive detail...
MAP2K1 Q56P Refametinib lung adenocarcinoma sensitive detail...
MAP2K1 Q56P PD-0325901 lung adenocarcinoma sensitive detail...
BRAF mutant Trametinib lung adenocarcinoma sensitive detail...
NRAS mutant Trametinib lung adenocarcinoma resistant detail...
ABL1 R332W Imatinib lung adenocarcinoma sensitive detail...
ABL1 G321L Imatinib lung adenocarcinoma sensitive detail...
ABL1 T315I ABL1 R332W Imatinib lung adenocarcinoma resistant detail...
ABL1 R332W Dasatinib lung adenocarcinoma sensitive detail...
ABL1 G321L Dasatinib lung adenocarcinoma sensitive detail...
ABL1 T315I ABL1 R332W Dasatinib lung adenocarcinoma resistant detail...
IDH1 mutant Dasatinib lung adenocarcinoma resistant detail...
FGFR1 positive AZD4547 + AZD8055 lung adenocarcinoma sensitive detail...
FGFR1 positive AZD4547 + Vistusertib lung adenocarcinoma sensitive detail...
FGFR1 positive AZD4547 + Sirolimus lung adenocarcinoma sensitive detail...
BRAF G469L Vemurafenib lung adenocarcinoma no benefit detail...
BRAF N581S PF-00477736 + PF3644022 lung adenocarcinoma predicted - sensitive detail...
FGFR3 positive Rogaratinib lung adenocarcinoma predicted - sensitive detail...
BRAF G469A PLX8394 lung adenocarcinoma sensitive detail...
BRAF G466V PLX8394 lung adenocarcinoma sensitive detail...
BRAF V600E BRAF amp SCH772984 lung adenocarcinoma decreased response detail...
BRAF V600E BRAF amp Dabrafenib + SCH772984 + Trametinib lung adenocarcinoma sensitive detail...
ALK rearrange ALK G1123S Ceritinib lung adenocarcinoma predicted - resistant detail...
ALK rearrange ALK G1123S Alectinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK C1156Y ALK L1196M Crizotinib lung adenocarcinoma predicted - resistant detail...
FGFR1 amp PRN1371 lung adenocarcinoma sensitive detail...
BRAF V600E NRAS Q61K Dabrafenib + Trametinib lung adenocarcinoma predicted - resistant detail...
ALK rearrange ALK L1152R Alectinib lung adenocarcinoma predicted - sensitive detail...
ALK rearrange ALK L1152R Ceritinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK L1196M Crizotinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK F1174L ALK G1269A Belizatinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK F1174L ALK D1203N ALK G1269A Ceritinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK L1256F Lorlatinib lung adenocarcinoma resistant detail...
EML4 - ALK ALK L1256F Alectinib lung adenocarcinoma sensitive detail...
EML4 - ALK ALK T1151K Crizotinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK T1151K Ceritinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK Crizotinib lung adenocarcinoma predicted - sensitive detail...
ALK rearrange ALK L1196M Crizotinib lung adenocarcinoma predicted - resistant detail...
ALK rearrange ALK L1196M ALK D1203N Ceritinib lung adenocarcinoma predicted - resistant detail...
ALK rearrange ALK L1196M ALK D1203N Lorlatinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK C1156Y ALK G1269A Lorlatinib lung adenocarcinoma unknown detail...
ALK rearrange ALK C1156Y Lorlatinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK C1156Y ALK G1269A Lorlatinib + Saracatinib lung adenocarcinoma sensitive detail...
ALK rearrange ALK C1156Y Lorlatinib + Saracatinib lung adenocarcinoma sensitive detail...
EML4 - ALK ALK E1154K ALK G1202R ALK I1268V Crizotinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK E1154K ALK G1202R ALK I1268V Ceritinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK G1202R Brigatinib lung adenocarcinoma conflicting detail...
EML4 - ALK ALK T1151M ALK C1156Y ALK F1174L ALK G1202R ALK S1206F ALK G1269A Lorlatinib lung adenocarcinoma predicted - resistant detail...
ALK rearrange ALK G1269A Crizotinib lung adenocarcinoma predicted - resistant detail...
ALK rearrange ALK F1174L Ceritinib lung adenocarcinoma predicted - resistant detail...
TP53 R181L Doxorubicin + Nutlin-3a lung adenocarcinoma sensitive detail...
TP53 R175P Doxorubicin + Nutlin-3a lung adenocarcinoma no benefit detail...
TP53 R181E Doxorubicin + Nutlin-3a lung adenocarcinoma sensitive detail...
RET rearrange Cabozantinib lung adenocarcinoma predicted - sensitive detail...
BRAF G464V Trametinib lung adenocarcinoma no benefit detail...
BRAF G466A Trametinib lung adenocarcinoma no benefit detail...
BRAF D594G Trametinib lung adenocarcinoma no benefit detail...
BRAF N581S Trametinib lung adenocarcinoma no benefit detail...
BRAF G466V Trametinib lung adenocarcinoma no benefit detail...
BRAF G469A Trametinib lung adenocarcinoma conflicting detail...
CDKN2A loss Palbociclib lung adenocarcinoma predicted - sensitive detail...
PIK3CA mutant Capivasertib lung adenocarcinoma no benefit detail...
PTEN mutant Capivasertib lung adenocarcinoma no benefit detail...
EML4 - ALK Alvocidib lung adenocarcinoma sensitive detail...
EML4 - ALK Dinaciclib lung adenocarcinoma sensitive detail...
EML4 - ALK Alvocidib + Crizotinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK THZ1 lung adenocarcinoma sensitive detail...
ALK rearrange Conteltinib lung adenocarcinoma predicted - sensitive detail...
BRAF V600E Trametinib lung adenocarcinoma predicted - sensitive detail...
ALK rearrange Bevacizumab + Lorlatinib lung adenocarcinoma predicted - sensitive detail...
BRAF L597R Dabrafenib + Trametinib lung adenocarcinoma predicted - sensitive detail...
BRAF G469V Dabrafenib + Trametinib lung adenocarcinoma no benefit detail...
BRAF L597V Dabrafenib + Trametinib lung adenocarcinoma sensitive detail...
BRAF L597V Trametinib lung adenocarcinoma sensitive detail...
BRAF L597V Lifirafenib lung adenocarcinoma sensitive detail...
BRAF L597V LXH 254 lung adenocarcinoma sensitive detail...
BRAF G469A Dabrafenib + Trametinib lung adenocarcinoma sensitive detail...
BRAF G469A Lifirafenib lung adenocarcinoma sensitive detail...
BRAF G469A LXH 254 lung adenocarcinoma sensitive detail...
BRAF L597V Dabrafenib lung adenocarcinoma resistant detail...
BRAF L597V Encorafenib lung adenocarcinoma resistant detail...
BRAF L597V Vemurafenib lung adenocarcinoma resistant detail...
BRAF L597V Tovorafenib lung adenocarcinoma resistant detail...
BRAF G469A Dabrafenib lung adenocarcinoma resistant detail...
BRAF G469A Vemurafenib lung adenocarcinoma resistant detail...
BRAF G469A Tovorafenib lung adenocarcinoma resistant detail...
BRAF L597V LY3214996 lung adenocarcinoma resistant detail...
BRAF L597V MK-8353 lung adenocarcinoma resistant detail...
BRAF L597V Ravoxertinib lung adenocarcinoma resistant detail...
BRAF L597V Ulixertinib lung adenocarcinoma resistant detail...
BRAF G469A Ulixertinib lung adenocarcinoma resistant detail...
BRAF G469A Ravoxertinib lung adenocarcinoma resistant detail...
BRAF G469A MK-8353 lung adenocarcinoma resistant detail...
BRAF G469A LY3214996 lung adenocarcinoma resistant detail...
EML4 - RET RXDX-105 lung adenocarcinoma sensitive detail...
EML4 - RET Pralsetinib lung adenocarcinoma sensitive detail...
EML4 - RET Ponatinib lung adenocarcinoma predicted - sensitive detail...
EML4 - RET Trametinib lung adenocarcinoma conflicting detail...
EML4 - RET RXDX-105 + Trametinib lung adenocarcinoma no benefit detail...
EML4 - RET GSK2126458 + RXDX-105 lung adenocarcinoma predicted - sensitive detail...
EML4 - RET Volasertib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK S1206F Crizotinib lung adenocarcinoma predicted - sensitive detail...
RET rearrange Sunitinib lung adenocarcinoma no benefit detail...
EML4 - ALK ALK Q1188_L1190del Lorlatinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK G1202K Lorlatinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK A1200_G1201delinsW Alectinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK A1200_G1201delinsW Brigatinib lung adenocarcinoma predicted - sensitive detail...
ALK rearrange ROS1 rearrange Crizotinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK Alectinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK Ceritinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK Lorlatinib lung adenocarcinoma sensitive detail...
EML4 - ALK Brigatinib lung adenocarcinoma sensitive detail...
EML4 - ALK ALK I1171N ALK V1180L Alectinib lung adenocarcinoma predicted - resistant detail...
ALK fusion Lorlatinib lung adenocarcinoma predicted - sensitive detail...
ALK fusion Crizotinib lung adenocarcinoma predicted - sensitive detail...
ALK fusion Alectinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK F1174C ALK E1210K Lorlatinib lung adenocarcinoma predicted - sensitive detail...
BRAF G469A BRAF W604C Dabrafenib + Trametinib lung adenocarcinoma predicted - sensitive detail...
BRAF K601E Dabrafenib + Trametinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK G1202R Alectinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK G1202R Lorlatinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK T1151K ALK G1202R ALK S1206F Lorlatinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK G1202L Lorlatinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK E1129V ALK I1171T ALK F1174C ALK F1174L ALK F1174V ALK G1269A Crizotinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK E1129V ALK I1171T ALK F1174C ALK F1174L ALK F1174V ALK G1269A Brigatinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK F1174C Lorlatinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK F1174C ALK L1196M Lorlatinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK BRAF V600E Dabrafenib + Trametinib lung adenocarcinoma no benefit detail...
EML4 - ALK BRAF V600E Alectinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171S Crizotinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK I1171S Ceritinib lung adenocarcinoma predicted - sensitive detail...
ALK rearrange ALK T1151R Ceritinib lung adenocarcinoma predicted - resistant detail...
ALK rearrange ALK T1151R Brigatinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171S Alectinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK I1171S Brigatinib lung adenocarcinoma predicted - sensitive detail...
BRAF T599dup Dabrafenib + Trametinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK BRAF A598_T599insV Alectinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK F1174L ALK S1189C Crizotinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK F1174L ALK S1189C Ceritinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK Ensartinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171N Alectinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK I1171N Ensartinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171N ALK G1202R Lorlatinib lung adenocarcinoma predicted - sensitive detail...
BRAF V600E MAP2K1 K57N Dabrafenib + Trametinib lung adenocarcinoma predicted - resistant detail...
BRAF V600E PTEN N329fs Dabrafenib lung adenocarcinoma predicted - resistant detail...
ALK positive Alectinib lung adenocarcinoma predicted - sensitive detail...
ALK rearrange Alectinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK F1174L ALK E1210K Brigatinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK F1174L ALK E1210K ALK G1269A Lorlatinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171T ALK F1174L ALK L1196M ALK D1203N ALK E1210K ALK G1269A Lorlatinib lung adenocarcinoma predicted - resistant detail...
ALK D1225N Crizotinib lung adenocarcinoma predicted - sensitive detail...
ALK D1225N Ensartinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK A1200V Crizotinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK V1180L Alectinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK G1269A Crizotinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK IDH2 R140Q Alectinib lung adenocarcinoma predicted - resistant detail...
ALK del exon2-19 Alectinib lung adenocarcinoma predicted - sensitive detail...
BRAF G469V Gefitinib lung adenocarcinoma sensitive detail...
BRAF G469V Afatinib lung adenocarcinoma sensitive detail...
BRAF G469V Osimertinib lung adenocarcinoma sensitive detail...
EML4 - ALK ALK D1203N Crizotinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK D1203N Lorlatinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK L1196M ALK D1203N Lorlatinib lung adenocarcinoma predicted - resistant detail...
ALK fusion Brigatinib lung adenocarcinoma predicted - sensitive detail...
BRAF G466V Dabrafenib + Trametinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK G1269A Brigatinib lung adenocarcinoma sensitive detail...
EML4 - ALK ALK G1269A Ceritinib lung adenocarcinoma sensitive detail...
BRAF N486_P490del Dabrafenib + Trametinib lung adenocarcinoma predicted - sensitive detail...
ATM E473* ATM loss ART0380 lung adenocarcinoma sensitive detail...
CDKN2A A17fs Palbociclib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171N Brigatinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171N Lorlatinib lung adenocarcinoma predicted - sensitive detail...
BRAF V600_W604delinsR Dabrafenib + Trametinib lung adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01579994 Phase I Crizotinib + Ganetespib Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers Completed USA 0
NCT01737502 Phase Ib/II Auranofin + Sirolimus Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Completed USA 0
NCT01814553 Phase III Afatinib + Loperamide ADAM-Afatinib Diarrhea Assessment and Management Completed USA 0
NCT01877083 Phase II Lenvatinib Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung Completed USA 4
NCT01877811 Phase Ib/II RXDX-105 CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 Completed USA 0
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Completed USA | FRA | ESP | DEU 3
NCT02185690 Phase I Binimetinib + Carboplatin + Pemetrexed Disodium A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung Completed CAN 0
NCT02231164 Phase III Docetaxel Nintedanib LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research Terminated USA 2
NCT02264678 Phase Ib/II Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting USA | GBR | FRA | ESP | CAN | BEL | AUS 2
NCT02285855 Phase II Metformin Metformin in Non Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT02450175 Phase I Letrozole Everolimus Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls Unknown status USA 0
NCT02450591 Phase I Erlotinib Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations Completed USA 0
NCT02466568 Phase Ib/II Nivolumab Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung Withdrawn 0
NCT02503358 Phase I Paclitaxel + Selumetinib Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Completed USA 0
NCT02513667 Phase II Ceritinib Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma Terminated USA 0
NCT02705339 Phase II Rociletinib Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) Withdrawn 0
NCT02759835 Phase II Osimertinib Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib Completed USA 0
NCT02839681 Phase II Anetumab ravtansine Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma Terminated USA 0
NCT02856425 Phase I Nintedanib + Pembrolizumab Trial Of Pembrolizumab And Nintedanib (PEMBIB) Recruiting FRA 0
NCT02864992 Phase II Tepotinib Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU | BEL | AUT 7
NCT03076164 Phase Ib/II Erlotinib + Trametinib A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib Completed USA 0
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Completed USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUS 3
NCT03255083 Phase I DS-1205c + Osimertinib DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Terminated 1
NCT03371381 Phase Ib/II JNJ-64041757 + Nivolumab Nivolumab An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung Terminated USA | ESP | BEL 0
NCT03476681 Phase I NEO-201 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting USA 0
NCT03611868 Phase Ib/II APG-115 + Pembrolizumab A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Recruiting USA | AUS 0
NCT03696212 Phase Ib/II Grapiprant + Pembrolizumab Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma Terminated USA 0
NCT03704688 Phase Ib/II Ponatinib + Trametinib Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT03709147 Phase II Carboplatin + Metformin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Metformin + Pembrolizumab + Pemetrexed Disodium Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma (FAME) Unknown status ITA 0
NCT03865511 Phase II Osimertinib MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib (MELROSE) Active, not recruiting FRA 0
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Active, not recruiting USA | ESP | CAN | BEL 0
NCT03944772 Phase II Necitumumab + Osimertinib Osimertinib + Selpercatinib Alectinib + Osimertinib Carboplatin + Durvalumab + Pemetrexed Disodium Osimertinib + Savolitinib Gefitinib + Osimertinib Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD) Active, not recruiting USA | NLD | ITA | ESP 5
NCT03970746 Phase Ib/II PDC*lung01 + Pembrolizumab PDC*lung01 + Pemetrexed Disodium PDC*lung01 Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC Active, not recruiting NLD | FRA | DEU | BEL 1
NCT04022876 Phase I ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Terminated USA | ITA | ESP | DEU 3
NCT04105270 Phase II Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial Recruiting USA 0
NCT04145622 Phase Ib/II Ifinatamab deruxtecan Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting USA 1
NCT04180371 Phase Ib/II BT5528 + Nivolumab BT5528 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression Recruiting USA | GBR | ESP | BEL 1
NCT04263090 Phase Ib/II Nivolumab + Rigosertib Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment Completed USA 0
NCT04300556 Phase Ib/II MORAb-202 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types Recruiting USA | GBR | FRA | ESP 0
NCT04339218 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma (CRYOMUNE) Recruiting FRA 0
NCT04393298 Phase Ib/II UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors Completed USA | GBR 0
NCT04424641 Phase Ib/II GEN1044 A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors Terminated USA | ESP 2
NCT04545710 Phase II Abemaciclib + Osimertinib Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance Active, not recruiting USA 0
NCT04557449 Phase I Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) Recruiting USA | GBR 6
NCT04672434 Phase I Sym021 + Sym024 Sym024 Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA | CAN 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04691375 Phase I Pembrolizumab + PY314 PY314 A Study of PY314 in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04748419 Phase Ib/II Durvalumab Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab Recruiting USA 0
NCT04870034 Phase I Binimetinib + Palbociclib Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer Withdrawn USA 0
NCT04939701 Phase Ib/II ASP0739 + Pembrolizumab ASP0739 Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants Completed USA 0
NCT04973163 Phase I BI 1823911 + Midazolam BI 1701963 + BI 1823911 A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation Active, not recruiting USA | GBR | ESP | BEL 0
NCT04991025 Phase II Certolizumab pegol + Cisplatin + Gemcitabine + Nivolumab Certolizumab pegol + Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Certolizumab pegol + Gemcitabine + Nivolumab Carboplatin + Certolizumab pegol + Nivolumab + Pemetrexed Disodium Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery Recruiting USA 0
NCT04991740 Phase I JNJ-78306358 A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors Completed ESP 1
NCT05015010 Phase II Alectinib Alectinib in Neo-adjuvant Treatment of Stage III NSCLC (ALNEO) Recruiting ITA 0
NCT05038150 Phase I SGN1 Study of SGN1 in Patients With Advanced Solid Tumor Recruiting USA 1
NCT05101356 Phase Ib/II LabVax 3(22)-23 + Sargramostim LabVax 3(22)-23 + Pembrolizumab + Sargramostim A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma Recruiting USA 0
NCT05103345 Phase I SGN1 Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor Recruiting 2
NCT05198830 Phase II Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + TRC102 Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer Recruiting USA 0
NCT05240131 Phase Ib/II Atezolizumab + GB1211 A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). Active, not recruiting FRA | ESP 1
NCT05254184 Phase I Ipilimumab + Nivolumab + Poly ICLC + Pooled Mutant KRAS-Targeted Long Peptide Vaccine KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC Recruiting USA 0
NCT05397093 Phase I ITIL-306 ITIL-306 in Advanced Solid Tumors Active, not recruiting USA 0
NCT05498597 Phase I AMT-151 AMT-151 in Patients With Selected Advanced Solid Tumours Recruiting AUS 1
NCT05512377 Phase II BI 907828 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Recruiting USA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 6
NCT05577715 Phase II MORAb-202 A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) Recruiting USA | FRA | ESP | BEL | AUS 1
NCT05607498 Phase I EMB-07 First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors Recruiting AUS 1
NCT05676749 Phase I Aldesleukin + C-TIL051 + Pembrolizumab C-TIL051 in Non-Small Cell Lung Cancer Recruiting USA 0
NCT05693090 Phase I Osimertinib + Tipifarnib Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer Withdrawn USA 0
NCT05709821 Phase Ib/II Pembrolizumab IMM60 IMM60 + Pembrolizumab IMM60 and Pembrolizumab in Melanoma and NSCLC Terminated USA | GBR | ESP 0
NCT05733000 Phase II CPI-613 + Gemcitabine + Hydroxychloroquine CPI-613 + Hydroxychloroquine CPI-613 + Gemcitabine CPI-613 + Fluorouracil + Hydroxychloroquine CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Recruiting USA 0
NCT05860296 Phase Ib/II Pembrolizumab + SLC-391 Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers Recruiting USA | CAN 0
NCT05948865 Phase I CPO301 A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors Recruiting USA | CAN 0
NCT05954871 Phase I Cetuximab + GDC-1971 GDC-1971 + Osimertinib Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer Recruiting USA | CAN | AUS 1
NCT06014658 Phase I MBRC-101 Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors Recruiting USA 0
NCT06178614 Phase I JNJ-87890387 A Study of JNJ-87890387 for Advanced Solid Tumors Recruiting USA | FRA | ESP 0
NCT06225427 Phase I Gilteritinib Gilteritinib for the Treatment of ALK NSCLC Recruiting USA 0
NCT06240728 Phase I NPX887 A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA-2/B7-H7 Recruiting USA 0